OncoMatch

OncoMatch/Clinical Trials/NCT06313957

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Is NCT06313957 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies LUCAR-20SP cells for relapsed b-cell non-hodgkin lymphoma.

Phase 1RecruitingPeking University Cancer Hospital & InstituteNCT06313957Data as of Jun 2026Location: China

Treatment: LUCAR-20SP cellsThis is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

LUCAR-20SP cells

Cancer type

Non-Hodgkin Lymphoma

Biomarker criteria

Required: CD20 positive

CD20 positive

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: allogeneic cell and gene therapy (CAR-T)

Exception: subjects with evidence that previous allogeneic cell and gene therapy products (such as CAR-positive T cells and CAR transgenes) in the subject have been below the lower limit of detection

Previous treatment with allogeneic cell and gene therapy (such as CAR-T); Except subjects with evidence that previous allogeneic cell and gene therapy products (such as CAR-positive T cells and CAR transgenes) in the subject have been below the lower limit of detection

Cannot have received: allogeneic hematopoietic stem cell transplantation

Previously received allogeneic hematopoietic stem cell transplantation

Cannot have received: gene therapy

Previously received gene therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06313957 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior allogeneic cell and gene therapy, allogeneic hematopoietic stem cell transplantation, gene therapy disqualifies patients from enrollment.

Does this trial require CD20?

Yes, CD20 positive is a required biomarker for enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify